Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis

Inclusion Criteria:

• Study participant must be ≥18 years of age at the time of signing the informedconsent form (ICF)

• Study participant has documented diagnosis of generalized myasthenia gravis (gMG) atthe Screening Visit based on study participant's history and supported by previousevaluation

• Study participant has a confirmed positive record of autoantibodies againstacetylcholine receptor (AChR) or muscle-specific kinase (MuSK) documented in themedical history at the Screening Visit

• Study participant has Myasthenia Gravis Foundation of America (MGFA) ClinicalClassification II to IV at Screening Visit.

• Study participant with a myasthenia gravis-activities of daily living (MG-ADL) scoreof at least 3 points from non-ocular symptoms and a quantitative myasthenia gravis (QMG) score of at least 11 at the Screening and Baseline visits in the firstTreatment Cycle.

• Study participant is considered for additional treatment by the investigator

• Body weight ≥35kg at the Screening Visit

Exclusion Criteria:

• Study participant has a known hypersensitivity to any components of the study drugor any other anti-neonatal Fc receptor (anti-FcRn) medications

• Study participant has a clinically important active infection including unresolvedor not adequately treated infection in the opinion of the investigator

• Study participant with a known tuberculosis (TB) infection, at high risk ofacquiring TB infection, or latent tuberculosis infection (LTBI), or current/historyof nontuberculous mycobacterial infection (NTMBI)

• Study participant has previously received rozanolixizumab drug product

• Study participant has received any vaccine in the 4 weeks prior to the initiation ofrozanolixizumab treatment or intends to receive any vaccine within 2 weeks after thelast infusion of rozanolixizumab. Note: For participants that are on rozanolixizumabtreatment, vaccination with live or live-attenuated vaccines is not recommended.During the whole study period, all other vaccines should take place at least 2 weeksafter the last infusion of a Treatment Cycle and 4 weeks before initiating the nextcycle

• Study participant has been treated with prohibited immunosuppressants, biologics,and other therapies within the timeframe shorter than the treatment-free period

• Study participant with severe (defined as Grade 3 on the MG-ADL scale) weaknessaffecting oropharyngeal or respiratory muscles, or who has myasthenic crisis orimpending crisis. Note: Impending Crisis is defined as bulbar or respiratorysymptoms of a patient who significantly worsens in a short time (≤2 weeks) and meetMGFA IVb or score 3 in one QMG bulbar muscle item, or score 2 in respiratory muscleitem, or bulbar+respiratory items score ≥4